Research ArticleCancer

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

See allHide authors and affiliations

Science Translational Medicine  12 Dec 2018:
Vol. 10, Issue 471, eaau0417
DOI: 10.1126/scitranslmed.aau0417

Enabling immunotherapy with an oncolytic virus

Immunotherapy treatments have been pioneered in the setting of melanoma, and although subsets of patients are able to survive long term, some tumors are resistant. Bommareddy and colleagues inquired whether combining certain treatments may lead to even better therapeutic responses. They examined two approved therapies, an oncolytic herpesvirus and a MEK inhibitor. This combination led to increased survival in mouse melanoma models, which was further extended with the addition of PD-1 blockade. The immune response behind this enhanced antitumor activity was dissected. The results of these studies suggest that combining these treatments may be beneficial for patients with melanoma.

View Full Text

Stay Connected to Science Translational Medicine